CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barackman, J. D.
Right arrow Articles by O'Hagan, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barackman, J. D.
Right arrow Articles by O'Hagan, D. T.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, May 2001, p. 652-657, Vol. 8, No. 3
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.3.652-657.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization

John D. Barackman,* Gary Ott, Samuel Pine, and Derek T. O'Hagan

Chiron Corporation, Emeryville, California 94608

Received 1 December 2000/Returned for modification 16 January 2001/Accepted 19 March 2001

Mucosal immunization strategies are actively being pursued in the hopes of improving the efficacy of vaccines against the influenza virus. Our group investigated the oral immunization of mice via intragastric gavage with influenza hemagglutinin (HA) combined with mutant Escherichia coli heat-labile enterotoxins K63 (LT-K63) and R72 (LT-R72). These oral immunizations resulted in potent serum antibody and HA inhibition titers, in some cases stronger than those obtained with traditional intramuscular administration, in addition to HA-specific immunoglobulin A in the saliva and nasal secretions. This study demonstrates that it may be possible to develop effective oral influenza vaccines.

* Corresponding author. Mailing address: Chiron Corporation, 4560 Horton St., Bldg. M-2, Emeryville, CA 94608. Phone: (510) 923-8194. Fax: (510) 923-4116. E-mail: john_barackman{at}cc.chiron.com.

Clinical and Diagnostic Laboratory Immunology, May 2001, p. 652-657, Vol. 8, No. 3
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.3.652-657.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.